- Home
- IOBT vs HIND Comparison
IOBT vs HIND Comparison
Compare IOBT & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IOBT | HIND |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 28.0M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IOBT | HIND |
|---|---|---|
| Price | $0.20 | $2.29 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 890.1K | 89.1K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $1.75 |
| 52 Week High | $2.79 | $12.87 |
Technical Indicators
Market Signals| Indicator | IOBT | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 34.65 |
| Support Level | N/A | $1.75 |
| Resistance Level | $0.40 | $2.93 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 4.92 | 0.00 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.